文献速递临床试验与 GCP

塞拉利昂埃博拉突发公共卫生事件期间资源有限环境下的临床试验监管

Regulating clinical trials in a resource-limited setting during the Ebola public health emergency in Sierra Leone.
PubMed 文献 · Trials · 2022-06-06

本文探讨塞拉利昂药事委员会及其药物安全与临床试验专家委员会在埃博拉疫情期间对临床试验的监管决策与经验教训。该独立专家委员会在10至15个工作日内完成评估并向药事委员会提供科学意见,以支持所有临床试验的审批,并请求非洲疫苗监管论坛协助审评及美国食品药品监督管理局通过单边承认与依赖谅解备忘录提供支持。埃博拉疫情暴露了该国临床试验监管结构与流程的诸多薄弱环节,政府和合作伙伴应进一步提供更多资源以建设临床试验结构与系统。

要点

  • 塞拉利昂药事委员会专家委员会在10至15个工作日内完成临床试验评估并提供科学意见。
  • 该委员会请求非洲疫苗监管论坛协助审评及美国食品药品监督管理局通过单边承认与依赖谅解备忘录提供支持。
  • 埃博拉疫情暴露了该国临床试验监管结构与流程的诸多薄弱环节。

核心结论

  • 埃博拉疫情暴露了该国临床试验监管结构与流程的诸多薄弱环节。
  • 政府和合作伙伴应进一步提供更多资源以建设临床试验结构与系统,使该机构能更好地应对未来突发公共卫生事件。

研究设计与样本

  • 本文探讨塞拉利昂药事委员会通过其药物安全与临床试验专家委员会在埃博拉疫情期间对临床试验监管所做的决策及经验教训。
  • 该独立专家委员会在10至15个工作日内完成评估并向塞拉利昂药事委员会提供科学意见,以支持所有临床试验的审批。

主要发现

  • 该独立专家委员会在10至15个工作日内完成评估并提供科学意见,以支持所有临床试验的审批。
  • 该委员会请求非洲疫苗监管论坛协助审评,并请求美国食品药品监督管理局通过单边承认与依赖谅解备忘录提供支持。
  • 该机构确保建立了不良事件和严重不良事件报告与审查、生物样本管理、进展报告提交与审查以及药物临床试验质量管理规范检查的结构和系统。
  • 埃博拉疫情暴露了该国临床试验监管结构与流程的诸多薄弱环节。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials during public health emergencies of novel medical products such as therapeutics and vaccines in resource-limited settings are daunting due to the limited capacity for regulatory assessment. Regulating clinical trials during the Ebola outbreak in Sierra Leone required expedited evaluation to identify medical products that could be promptly introduced to combat the epidemic in the absence of approved treatment or prevention. This article explored the decisions taken by the Pharmacy Board of Sierra Leone through its Expert Committee on Medicine Safety and Clinical Trials regarding clinical trials oversight during the Ebola epidemic and the lessons learned. This independent expert committee assessed and provided scientific opinions to the Pharmacy Board of Sierra Leone to inform approval of all clinical trials within 10-15 working days. We also requested for assisted review from the African Vaccine Regulatory Forum and support from the US Food and Drug Administration through a unilateral recognition and reliance memorandum of understanding. In addition, the Agency-ensured structures and systems were in place for reporting and reviewing adverse events and serious adverse events, management of biological samples, submission and review of progress reports, and good clinical practice inspections. Unfortunately, the Ebola epidemic revealed many weaknesses in the country's clinical trials regulatory structure and processes. Government and partners should further offer more resources to build the clinical trial structures and systems so that the Agency will be better poised to handle future public health emergencies.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Abiri OT, Bah AJ, Lahai M, et al. Regulating clinical trials in a resource-limited setting during the Ebola public health emergency in Sierra Leone. Trials. 2022. PMID: 35668457. doi:10.1186/s13063-022-06416-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。